tradingkey.logo
搜尋

Anika Therapeutics Inc

ANIK
添加自選
19.250USD
+1.180+6.53%
收盤 07-31 16:00美東報價延遲15分鐘
257.12M總市值
虧損本益比TTM

關於 Anika Therapeutics Inc 公司

Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.

Anika Therapeutics Inc簡介

公司代碼ANIK
公司名稱Anika Therapeutics Inc
上市日期May 16, 1985
CEOBlanchard (Cheryl Renee)
員工數量288
證券類型Ordinary Share
年結日May 16
公司地址32 Wiggins Ave
城市BEDFORD
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編01730-2315
電話17814579000
網址https://anika.com/
公司代碼ANIK
上市日期May 16, 1985
CEOBlanchard (Cheryl Renee)

Anika Therapeutics Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Stephen D. (Steve) Griffin
Mr. Stephen D. (Steve) Griffin
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
90.25K
+10.05%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
52.97K
+19.64%
Dr. Glenn R. Larsen, Ph.D.
Dr. Glenn R. Larsen, Ph.D.
Independent Director
Independent Director
50.26K
--
Mr. Joseph H. (Joe) Capper
Mr. Joseph H. (Joe) Capper
Independent Director
Independent Director
30.80K
+33.77%
Mr. William R. (Bill) Jellison
Mr. William R. (Bill) Jellison
Independent Director
Independent Director
23.10K
--
Dr. Cheryl Renee Blanchard, Ph.D.
Dr. Cheryl Renee Blanchard, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Susan L. N. Vogt
Ms. Susan L. N. Vogt
Independent Director
Independent Director
--
--
Mr. David B. Colleran, J.D.
Mr. David B. Colleran, J.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
--
--
Mr. John Bell (Jack) Henneman, III
Mr. John Bell (Jack) Henneman, III
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Stephen O. Richard
Mr. Stephen O. Richard
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Stephen D. (Steve) Griffin
Mr. Stephen D. (Steve) Griffin
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
90.25K
+10.05%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
52.97K
+19.64%
Dr. Glenn R. Larsen, Ph.D.
Dr. Glenn R. Larsen, Ph.D.
Independent Director
Independent Director
50.26K
--
Mr. Joseph H. (Joe) Capper
Mr. Joseph H. (Joe) Capper
Independent Director
Independent Director
30.80K
+33.77%
Mr. William R. (Bill) Jellison
Mr. William R. (Bill) Jellison
Independent Director
Independent Director
23.10K
--
Dr. Cheryl Renee Blanchard, Ph.D.
Dr. Cheryl Renee Blanchard, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--

常見問題

Anika Therapeutics Inc的前五大股東是誰?

Anika Therapeutics Inc的前五大股東如下:Mr. Stephen D. (Steve) Griffin

有多少機構持有Anika Therapeutics Inc(ANIK)的股份?

截至2026Q1,共有264家機構持有Anika Therapeutics Inc的股份,合計持有的股份價值約為12.85M,占公司總股份的96.55% 。與2025Q4相比,機構持股有所增加,增幅為-1611291.00。

哪個業務部門對Anika Therapeutics Inc的收入貢獻最大?

在2026Q1,OEM Channel業務部門對Anika Therapeutics Inc的收入貢獻最大,創收64.41M,占總收入的57.09% 。
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有